Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis

被引：0
|
作者：
Giuseppe A. Colloca
Antonella Venturino
Domenico Guarneri
机构：
[1] Ospedale Civile di Sanremo,Department of Oncology
来源：
International Journal of Clinical Oncology | 2019年 / 24卷
关键词：
Early tumor shrinkage; Chemotherapy; Endpoint; Prognosis; Bevacizumab; Cetuximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：231 / 240
页数：9
相关论文
共 50 条
  • [31] Early tumor shrinkage as a predictor of favorable outcomes in patients with unresectable metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab
    Behourah, Z.
    Ameziane, N.
    Aida, M.
    Messaoud, M. Ahed
    Bousahba, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S178 - S178
  • [32] Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial
    Modest, Dominik P.
    Laubender, Ruediger P.
    Stintzing, Sebastian
    Giessen, Clemens
    Schulz, Christoph
    Haas, Michael
    Mansmann, Ulrich
    Heinemann, Volker
    ACTA ONCOLOGICA, 2013, 52 (05) : 956 - 962
  • [33] Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial.
    Modest, Dominik Paul
    Laubender, Ruediger Paul
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Stauch, Martina
    Hass, Holger
    Dietzfelbinger, Hermann F.
    Oruzio, Daniel V.
    Klein, Stefan
    Zellmann, Klaus
    Decker, Thomas
    Schulze, Mathias
    Abenhardt, Wolfgang
    Puchtler, Gerhard
    Kappauf, Herbert W.
    Mittermueller, Johann
    Haberl, Christopher
    Stintzing, Sebastian
    Mansmann, Ulrich Robert
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Early tumor shrinkage as an indicator of treatment efficacy in metastatic colorectal cancer treatment
    Heinemann, V
    Modest, D.
    Laubender, R. P.
    Giessen, C.
    Mansmann, U.
    Stintzing, S.
    ONKOLOGIE, 2012, 35 : 254 - 254
  • [35] The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
    Holch, Julian Walter
    Ricard, Ingrid
    Stintzing, Sebastian
    Modest, Dominik Paul
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2017, 70 : 87 - 98
  • [36] Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
    Ridouane, Yassine
    Lopes, Gilberto
    Ku, Geoffrey
    Masud, Hasan
    Haaland, Benjamin
    ONCOTARGET, 2017, 8 (39) : 66458 - 66466
  • [37] Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer A meta-analysis
    Yang, Ya-Fan
    Wang, Gui-Ying
    He, Jing-Li
    Wu, Feng-Peng
    Zhang, Yan-Ni
    MEDICINE, 2017, 96 (12)
  • [38] The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta- analysis of randomized trials
    Jang, Hyun Joo
    Kim, Bum Jun
    Kim, Jung Han
    Kim, Hyeong Su
    ONCOTARGET, 2017, 8 (42) : 73009 - 73016
  • [39] Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis
    Sun, Z-W
    Lan, X-Y
    Kong, F-L
    Gao, Y-Y
    Li, S.
    Xi, Y-L
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (17) : 5365 - 5373
  • [40] First-line treatment choices of Turkish medical oncologists in metastatic colorectal cancer: A survey study
    Beypinar, Ismail
    Araz, Murat
    Uysal, Mukremin
    Yalcin, Suayib
    JOURNAL OF BUON, 2019, 24 (01): : 68 - 76
12345